Company Overview and News

 
Case for gender diversity on boards will survive the post-AMP backlash

2018-05-12 theage.com.au
It was a sharply-worded question, read aloud almost two hours into the fractious and agonisingly drawn-out annual meeting of troubled wealth giant AMP.

 
Case for gender diversity on boards will survive the post-AMP backlash

2018-05-12 smh.com.au
It was a sharply-worded question, read aloud almost two hours into the fractious and agonisingly drawn-out annual meeting of troubled wealth giant AMP.

 
'The ship has sailed' - push back against on women on boards will fail

2018-05-11 theage.com.au
It was a sharply-worded question, read aloud almost two hours into the fractious and agonisingly drawn-out annual meeting of troubled wealth giant AMP.

 
'The ship has sailed' - push back against on women on boards will fail

2018-05-11 smh.com.au
It was a sharply-worded question, read aloud almost two hours into the fractious and agonisingly drawn-out annual meeting of troubled wealth giant AMP.

 
Reserve Bank to sell Melbourne headquarters

2018-04-10 theage.com.au
The Reserve Bank of Australia is set to offload a prime Collins Street building in Melbourne in a move that will boost government coffers by an estimated $110 million.

 
Reserve Bank to sell Melbourne headquarters

2018-04-10 smh.com.au
The Reserve Bank of Australia is set to offload a prime Collins Street building in Melbourne in a move that will boost government coffers by an estimated $110 million.

 
Mirvac Group 2018 Q2 - Results - Earnings Call Slides

2018-02-08 seekingalpha
The following slide deck was published by Mirvac Group in conjunction with their 2018 Q2 earnings call.

 
S&P/ASX 200 strengthens in afternoon trading

2018-02-08 proactiveinvestors.com.au
There weren’t any substantial moves in afternoon trading with the telecommunications and financial sectors providing most of the support.

 
S&P/ASX 200 breaks into positive territory at midday

2018-02-08 proactiveinvestors.com.au
S&P/ASX 200 (XJO) recovered all of the lost ground from the opening bell sell-off to move into positive territory by midday as it hit a high of 5880 points.

 
S&P/ASX 200 trading slightly lower but trying to rebound

2018-02-08 proactiveinvestors.com.au
S&P/ASX 200 (XJO) fell circa 40 points to 5838 points within the first 10 minutes of trading.

 
S&P/ASX 200 closes up 43 points after late afternoon jitters

2018-02-07 proactiveinvestors.com.au
S&P/ASX 200 (XJO) retraced from circa 5900 points to 5876 points in the last hour of trading.

 
Mirvac plan targets first home buyers

2017-11-30 businessnews.com.au
Listed property developer Mirvac Group has launched a new campaign to tackle affordability in the first home buyers market with the release of apartments at its Latitude Leighton Beach development.  

 
ASX slides into the red as consumer stock weigh

2017-09-19 theage.com.au
A choppy session for the sharemarket ended on a weak note on Tuesday, with stocks that benefit from a strong consumer suffering after the RBA singled rising household debt and stagnant wage growth out again as reasons to remain cautious about the economy.  

 
ASX slides into the red as consumer stock weigh

2017-09-19 smh.com.au
A choppy session for the sharemarket ended on a weak note on Tuesday, with stocks that benefit from a strong consumer suffering after the RBA singled rising household debt and stagnant wage growth out again as reasons to remain cautious about the economy.  

 
Finance news you need to know today

2017-08-17 perthnow.com.au
THE Australian market looks set to open sharply lower after Wall Street’s indexes slumped with the Dow down more than one per cent and the Nasdaq dropping close to two per cent. At 0700 AEST on Friday, the share price futures index was down 51 points, or 0.89 per cent, at 5,695.

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

2018-05-25 - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

2018-05-25 - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...